Cargando…
Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial
PURPOSE: A phase I clinical trial was conducted to evaluate the immunogenicity and safety of newly developed egg-cultivated trivalent inactivated split influenza vaccine (TIV) in Korea. MATERIALS AND METHODS: The TIV was administered to 43 healthy male adults. Subjects with high pre-existing titers...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011266/ https://www.ncbi.nlm.nih.gov/pubmed/27593862 http://dx.doi.org/10.3349/ymj.2016.57.6.1354 |
_version_ | 1782451795855933440 |
---|---|
author | Kang, Kyuri Han, Seunghoon Hong, Taegon Jeon, Sangil Paek, Jeongki Kang, Jin Han Yim, Dong-Seok |
author_facet | Kang, Kyuri Han, Seunghoon Hong, Taegon Jeon, Sangil Paek, Jeongki Kang, Jin Han Yim, Dong-Seok |
author_sort | Kang, Kyuri |
collection | PubMed |
description | PURPOSE: A phase I clinical trial was conducted to evaluate the immunogenicity and safety of newly developed egg-cultivated trivalent inactivated split influenza vaccine (TIV) in Korea. MATERIALS AND METHODS: The TIV was administered to 43 healthy male adults. Subjects with high pre-existing titers were excluded in a screening step. Immune response was measured by a hemagglutination inhibition (HI) assay. RESULTS: The seroprotection rates against A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2009 were 74.42% [95% confidence interval (CI): 61.38–87.46], 72.09% (95% CI: 58.69–85.50), and 86.05% (95% CI: 75.69–96.40), respectively. Calculated seroconversion rates were 74.42% (95% CI: 61.38–87.46), 74.42% (95% CI: 61.38–87.46), and 79.07% (95% CI: 66.91–91.23), respectively. There were 25 episodes of solicited local adverse events in 21 subjects (47.73%), 21 episodes of solicited general adverse events in 16 subjects (36.36%) and 5 episodes of unsolicited adverse events in 5 subjects (11.36%). All adverse events were grade 1 or 2 and disappeared within three days. CONCLUSION: The immunogenicity and safety of TIV established in this phase I trial are sufficient to plan a larger scale clinical trial. |
format | Online Article Text |
id | pubmed-5011266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Yonsei University College of Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-50112662016-11-01 Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial Kang, Kyuri Han, Seunghoon Hong, Taegon Jeon, Sangil Paek, Jeongki Kang, Jin Han Yim, Dong-Seok Yonsei Med J Original Article PURPOSE: A phase I clinical trial was conducted to evaluate the immunogenicity and safety of newly developed egg-cultivated trivalent inactivated split influenza vaccine (TIV) in Korea. MATERIALS AND METHODS: The TIV was administered to 43 healthy male adults. Subjects with high pre-existing titers were excluded in a screening step. Immune response was measured by a hemagglutination inhibition (HI) assay. RESULTS: The seroprotection rates against A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2009 were 74.42% [95% confidence interval (CI): 61.38–87.46], 72.09% (95% CI: 58.69–85.50), and 86.05% (95% CI: 75.69–96.40), respectively. Calculated seroconversion rates were 74.42% (95% CI: 61.38–87.46), 74.42% (95% CI: 61.38–87.46), and 79.07% (95% CI: 66.91–91.23), respectively. There were 25 episodes of solicited local adverse events in 21 subjects (47.73%), 21 episodes of solicited general adverse events in 16 subjects (36.36%) and 5 episodes of unsolicited adverse events in 5 subjects (11.36%). All adverse events were grade 1 or 2 and disappeared within three days. CONCLUSION: The immunogenicity and safety of TIV established in this phase I trial are sufficient to plan a larger scale clinical trial. Yonsei University College of Medicine 2016-11-01 2016-08-30 /pmc/articles/PMC5011266/ /pubmed/27593862 http://dx.doi.org/10.3349/ymj.2016.57.6.1354 Text en © Copyright: Yonsei University College of Medicine 2016 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kang, Kyuri Han, Seunghoon Hong, Taegon Jeon, Sangil Paek, Jeongki Kang, Jin Han Yim, Dong-Seok Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title | Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title_full | Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title_fullStr | Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title_full_unstemmed | Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title_short | Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial |
title_sort | immunogenicity and safety of trivalent split influenza vaccine in healthy korean adults with low pre-existing antibody levels: an open phase i trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011266/ https://www.ncbi.nlm.nih.gov/pubmed/27593862 http://dx.doi.org/10.3349/ymj.2016.57.6.1354 |
work_keys_str_mv | AT kangkyuri immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT hanseunghoon immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT hongtaegon immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT jeonsangil immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT paekjeongki immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT kangjinhan immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial AT yimdongseok immunogenicityandsafetyoftrivalentsplitinfluenzavaccineinhealthykoreanadultswithlowpreexistingantibodylevelsanopenphaseitrial |